Sertraline in the treatment of depressive disorders in patients with Parkinson's disease

Silvia Marino; Edoardo Sessa; Giuseppe Di Lorenzo; Giuseppina Digangi; Antonella Alagna; Placido Bramanti; Paolo Di Bella

doi:10.1007/s10072-008-1021-3

Sertraline in the treatment of depressive disorders in patients with Parkinson's disease

Silvia Marino, Edoardo Sessa, Giuseppe Di Lorenzo, Giuseppina Digangi, Antonella Alagna, Placido Bramanti, Paolo Di Bella

IRCCS Centro Neurolesi "Bonino Pulejo"

Research output: Contribution to journal › Article › peer-review

Abstract

We studied 54 idiopathic Parkinson's disease (PD) patients with depressive disorders (DD) to compare the efficacy and the effect of treatment with sertraline in the usual formulation and in the liquid oral concentrate (LOC) formulation. After 6 months of sertraline treatment, the Hamilton Depression Rating Scale and the Montgomery and Asberg Depression Rating Scale showed a decrement (p <0.001, for both formulations). Parkinson's Disease Questionnaire scores improved (p <0.005 for usual formulation and p

Original language	English
Pages (from-to)	391-395
Number of pages	5
Journal	Neurological Sciences
Volume	29
Issue number	6
DOIs	https://doi.org/10.1007/s10072-008-1021-3
Publication status	Published - 2008

Keywords

Depressive disorders
Parkinson's disease
Quality of life
Sertraline

ASJC Scopus subject areas

Dermatology
Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1007/s10072-008-1021-3

Fingerprint Dive into the research topics of 'Sertraline in the treatment of depressive disorders in patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this

@article{c4b0655cff594426ad43e81d5adb281d,

title = "Sertraline in the treatment of depressive disorders in patients with Parkinson's disease",

abstract = "We studied 54 idiopathic Parkinson's disease (PD) patients with depressive disorders (DD) to compare the efficacy and the effect of treatment with sertraline in the usual formulation and in the liquid oral concentrate (LOC) formulation. After 6 months of sertraline treatment, the Hamilton Depression Rating Scale and the Montgomery and Asberg Depression Rating Scale showed a decrement (p <0.001, for both formulations). Parkinson's Disease Questionnaire scores improved (p <0.005 for usual formulation and p ",

keywords = "Depressive disorders, Parkinson's disease, Quality of life, Sertraline",

author = "Silvia Marino and Edoardo Sessa and {Di Lorenzo}, Giuseppe and Giuseppina Digangi and Antonella Alagna and Placido Bramanti and {Di Bella}, Paolo",

year = "2008",

doi = "10.1007/s10072-008-1021-3",

language = "English",

volume = "29",

pages = "391--395",

journal = "Neurological Sciences",

issn = "1590-1874",

publisher = "Springer-Verlag Italia s.r.l.",

number = "6",

}

TY - JOUR

T1 - Sertraline in the treatment of depressive disorders in patients with Parkinson's disease

AU - Marino, Silvia

AU - Sessa, Edoardo

AU - Di Lorenzo, Giuseppe

AU - Digangi, Giuseppina

AU - Alagna, Antonella

AU - Bramanti, Placido

AU - Di Bella, Paolo

PY - 2008

Y1 - 2008

N2 - We studied 54 idiopathic Parkinson's disease (PD) patients with depressive disorders (DD) to compare the efficacy and the effect of treatment with sertraline in the usual formulation and in the liquid oral concentrate (LOC) formulation. After 6 months of sertraline treatment, the Hamilton Depression Rating Scale and the Montgomery and Asberg Depression Rating Scale showed a decrement (p <0.001, for both formulations). Parkinson's Disease Questionnaire scores improved (p <0.005 for usual formulation and p

AB - We studied 54 idiopathic Parkinson's disease (PD) patients with depressive disorders (DD) to compare the efficacy and the effect of treatment with sertraline in the usual formulation and in the liquid oral concentrate (LOC) formulation. After 6 months of sertraline treatment, the Hamilton Depression Rating Scale and the Montgomery and Asberg Depression Rating Scale showed a decrement (p <0.001, for both formulations). Parkinson's Disease Questionnaire scores improved (p <0.005 for usual formulation and p

KW - Depressive disorders

KW - Parkinson's disease

KW - Quality of life

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=58149102530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149102530&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-1021-3

DO - 10.1007/s10072-008-1021-3

M3 - Article

C2 - 19002650

AN - SCOPUS:58149102530

VL - 29

SP - 391

EP - 395

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 6

ER -